Spectrum Pharmaceuticals (SPPI) Earns Daily News Impact Score of 0.04
News headlines about Spectrum Pharmaceuticals (NASDAQ:SPPI) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spectrum Pharmaceuticals earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.1599859669602 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern’s analysis:
- Technical data from the actions of people on Spectrum Pharmaceuticals, Inc. (SPPI) – Wall Street Morning (wallstreetmorning.com)
- Spectrum Pharma Inc (SPPI) Is It Worthy for Investors? – ExpertGazette (expertgazette.com)
- Investor’s Roundup (Volatility in Focus) – Spectrum Pharmaceuticals, Inc., (NASDAQ: SPPI) – Stock Watch (stocksnewstimes.com)
- Investor’s Watch List: Spectrum Pharmaceuticals, Inc., (NASDAQ: SPPI), Aurinia Pharmaceuticals Inc., (NASDAQ … – Stocks In The News (press release) (tradingnewsnow.com)
- Stock Traders Purchase Large Volume of Spectrum Pharmaceuticals Call Options (SPPI) (americanbankingnews.com)
Spectrum Pharmaceuticals (NASDAQ:SPPI) opened at $18.92 on Monday. Spectrum Pharmaceuticals has a twelve month low of $4.17 and a twelve month high of $21.95. The company has a quick ratio of 4.89, a current ratio of 5.04 and a debt-to-equity ratio of 0.33.
SPPI has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Spectrum Pharmaceuticals in a report on Wednesday, August 16th. Guggenheim started coverage on Spectrum Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $32.00 price target for the company. Jefferies Group boosted their price target on Spectrum Pharmaceuticals to $25.00 and gave the company a “buy” rating in a report on Friday, October 20th. Zacks Investment Research downgraded Spectrum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Finally, ValuEngine raised Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $21.40.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Stock Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.